Acolbifene

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:Acolbifene, also known as EM-652, or SCH-57068, is a selective estrogen receptor modulator (SERM). Acolbifene is currently being studied in the prevention of breast cancer in women at high risk of breast cancer. EM-652 (SCH 57068) and the prodrug EM-800 (SCH57050) which are the most potent of the known antiestrogens. EM-652 is the compound having the highest affinity for the estrogen receptor, including estradiol. It has higher affinity for the ER than ICI 182780, hydroxytamoxifen, raloxifene, droloxifene and hydroxytoremifene. EM-652 has the most potent inhibitory activity on both ER alpha and ER beta compared to any of the other antiestrogens tested. EM-652 was also the most potent inhibitor of the percentage of cycling cancer cells. ( J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):51-84.)

Price and Availability

Acolbifene, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 204170Name: AcolbifeneCAS#: 182167-02-8 (free base)Chemical Formula: C29H31NO4Exact Mass: 457.22531Molecular Weight: 457.56074Elemental Analysis: C, 76.12; H, 6.83; N, 3.06; O, 13.99

Related CAS #:182167-02-8 (free base)252555-01-4 (HCl)

Synonym:EM 652; EM-652; EM652; SCH57068; SCH-57068; SCH 57068; Acolbifene.

IUPAC/Chemical Name:(S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-chromen-7-ol

InChi Key:DUYNJNWVGIWJRI-LJAQVGFWSA-N

InChi Code:InChI=1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3/t29-/m0/s1

SMILES Code:OC1=CC2=C(C=C1)C(C)=C(C3=CC=C(O)C=C3)[C@H](C4=CC=C(OCCN5CCCCC5)C=C4)O2

Technical Data

Additional Information

Acolbifene, formerly known as EM-652, and SCH 57068, is a third generation SERM acting as pure antiestrogen. Acolbifene is also the orally active antiestrogen which is the most potent of the known antiestrogens and exerts pure antiestrogenic activity in the mammary gland and endometrium. Acolbifene is currently in Phase II trials for the prevention of breast cancer sponsored by EndoCeutics, Quebec City, Canada. EM-652 inhibits the AF-1 and AF-2 functions of both ERalpha and beta while the inhibitory action of OH-TAM is limited to AF-2. EM-652 , thus, inhibits Ras-induced transcriptional activity and blocks SRC-1-stimulated activity of the two receptors. The absence of blockade of AF-1 by OH-TAM could explain why resistance develops to Tamoxifen treatment. Not only the development, but also the growth of established DMBA-induced mammary carcinoma is inhibited by treatment with EM-800, the prodrug of EM-652 . EM-652 is the most potent antiestrogen to inhibit the growth of human breast cancer ZR-75-1, MCF-7 and T-47D cells in vitro. When incubated with human Ishikawa endometrial carcinoma cells, EM-800 has no stimulatory effect on the estrogen-sensitive parameter alkaline phosphatase activity. When administered to ovariectomized animals, EM-800 prevents bone loss, and lowers serum cholesterol and triglyceride levels. EM-800 has shown benefits in women with breast cancer who had failed Tamoxifen. The above-summarized preclinical and clinical data clearly suggest the interest of studying this compounds in the neoadjuvant and adjuvant settings and, most importantly, for the prevention of breast and uterine cancer. (s ource: Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Tremblay A, Tremblay G. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):213-25 .)

References

1: Liby K, Rendi M, Suh N, Royce DB, Risingsong R,Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, SpornMB. The combination of the rexinoid, LG100268, and a selective estrogenreceptor modulator, either arzoxifene or acolbifene, synergizes in theprevention and treatment of mammary tumors in an estrogenreceptor-negative model of breast cancer. Clin Cancer Res. 2006 Oct1;12(19):5902-9. PubMed PMID: 17020999.

2: Al-Dhaheri MH, Shah YM, Basrur V, Pind S, Rowan BG. Identification ofnovel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifenein T47D breast cancer cells. Steroids. 2006 Nov;71(11-12):966-78. Epub2006 Sep 1. PubMed PMID: 16949628.

3: Lemieux C, Gélinas Y, Lalonde J, Labrie F, Richard D, Deshaies Y.Hypocholesterolemic action of the selective estrogen receptor modulatoracolbifene in intact and ovariectomized rats with diet-inducedhypercholesterolemia. Metabolism. 2006 May;55(5):605-13. PubMed PMID:16631436.

4: Lemieux C, Gélinas Y, Lalonde J, Labrie F, Richard D, Deshaies Y. Theselective estrogen receptor modulator acolbifene reduces cholesterolemiaindependently of its anorectic action in control and cholesterol-fedrats. J Nutr. 2005 Sep;135(9):2225-9. PubMed PMID: 16140902.

5: Berger L, El-Alfy M, Martel C, Labrie F. Effects ofdehydroepiandrosterone, Premarin and Acolbifene on histomorphology andsex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol.2005 Jul;96(2):201-15. PubMed PMID: 15979306.

6: Gauthier S, Cloutier J, Dory YL, Favre A, Mailhot J, Ouellet C,Schwerdtfeger A, Mérand Y, Martel C, Simard J, Labrie F. Synthesis andstructure-activity relationships of analogs of EM-652 (acolbifene), apure selective estrogen receptor modulator. Study of nitrogensubstitution. J Enzyme Inhib Med Chem. 2005 Apr;20(2):165-77. PubMedPMID: 15968821.

7: Lemieux C, Phaneuf D, Labrie F, Giguère V, Richard D, Deshaies Y.Estrogen receptor alpha-mediated adiposity-lowering andhypocholesterolemic actions of the selective estrogen receptor modulatoracolbifene. Int J Obes (Lond). 2005 Oct;29(10):1236-44. PubMed PMID:15925950.

8: Lemieux C, Gélinas Y, Lalonde J, Labrie F, Cianflone K, Deshaies Y.Hypolipidemic action of the SERM acolbifene is associated with decreasedliver MTP and increased SR-BI and LDL receptors. J Lipid Res. 2005Jun;46(6):1285-94. Epub 2005 Mar 1. PubMed PMID: 15741653.

9: Liu J, Liu H, van Breemen RB, Thatcher GR, Bolton JL. Bioactivationof the selective estrogen receptor modulator acolbifene to quinonemethides. Chem Res Toxicol. 2005 Feb;18(2):174-82. PubMed PMID:15720121.

10: Labrie F, Champagne P, Labrie C, Roy J, Laverdière J, Provencher L,Potvin M, Drolet Y, Pollak M, Panasci L, L"Espérance B, Dufresne J,Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P,Candas B. Activity and safety of the antiestrogen EM-800, the orallyactive precursor of acolbifene, in tamoxifen-resistant breast cancer. JClin Oncol. 2004 Mar 1;22(5):864-71. PubMed PMID: 14990642.